• Ali Haider Jafry, Austin LaGrow, Khawaja Hassan Akhtar, Ethan Hacker, Sage Russell, Brian Kliewer, and AsadZain Ul AbideenZUADepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States..
• Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States. Electronic address: ali-jafry@ouhsc.edu.
• Am. J. Med. Sci. 2022 Oct 1; 364 (4): 481491481-491.

AbstractSynthetic cannabinoids cannot be detected on a standard urine drug screen (UDS), making them a convenient drug of abuse. We report the first case of ST elevation myocardial infarction (STEMI) in a young patient due to coronary artery thrombosis secondary to synthetic cannabinoid use and concurrent COVID-19 infection. A 38-year-old previously healthy male developed severe chest pain and was found to have anterior STEMI and COVID-19 infection. Coronary angiography showed acute thrombotic occlusion of the mid-left anterior descending artery that was managed with thrombectomy and stent placement. He only required supportive care for COVID-19. A comprehensive literature search revealed 34 additional cases of STEMI with synthetic cannabinoid use; majority were males (97%) with mean age of 29 years. 29 patients (85.3%) underwent coronary angiography and majority had left anterior descending artery (LAD) involvement (55%), with 13 (44.8%) undergoing stent placement. We highlight STEMI as a potentially lethal complication of synthetic cannabinoids; prompt angiography may be lifesaving.Copyright © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

17 keywords...

hide…